569-57-3 | Chlorotrianisene

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$47.00	$33.00
25mg	98%	in stock	$96.00	$67.00

Description

• Catalog Number: AG64326
• Chemical Name: Chlorotrianisene
• CAS Number: 569-57-3
• Molecular Formula: C23H21ClO3
• Molecular Weight: 380.864
• MDL Number: MFCD00048044
• SMILES: COc1ccc(cc1)C(=C(c1ccc(cc1)OC)Cl)c1ccc(cc1)OC
• NSC Number: 10108

Computed Properties

• Complexity: 442
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 6
• XLogP3: 6.4

Literature

• FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.

  Chemico-biological interactions 20130905

• Treatments for suppression of lactation.

  The Cochrane database of systematic reviews 20120912

• Large-scale prediction and testing of drug activity on side-effect targets.

  Nature 20120621

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Treatments for suppression of lactation.

  The Cochrane database of systematic reviews 20090121

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• An inventory of yeast proteins associated with nucleolar and ribosomal components.

  Genome biology 20060101

• Tracing the origins of COX-2 inhibitors' structures.

  Current medicinal chemistry 20020801

• Mesenteric venous thrombosis associated with estrogen therapy for treatment of prostatic carcinoma.

  The Journal of urology 19850901

• The effect of chlorotrianisene as postpartum lactation suppression on blood coagulation factors.

  American journal of obstetrics and gynecology 19790701

• The choice of estrogen preparations in the treatment of prostatic cancer.

  Canadian Medical Association journal 19751108

• Hydroxyurea in stage D carcinoma of the prostate: a pilot study.

  The Journal of urology 19750901

• [Vascular accidents of estrogen therapy for prostatic cancer metastases].

  Journal d'urologie et de nephrologie 19731201